Generated by AI
Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. The company’s current portfolio centers on targeted drug candidates designed to address difficult-to-treat solid tumors through biomarker-guided approaches. Its development programs span multiple mechanisms, including agents that act on key nodes within the RAS/MAPK pathway and therapies intended to overcome resistance pathways in cancer cells. Erasca’s work is concentrated on precision medicine in oncology, with an emphasis on selecting patient populations most likely to benefit from its investigational treatments. Based in San Diego, California, Erasca plays a role in the biotechnology market as a research-driven company advancing experimental cancer therapies through clinical development and collaborative studies.
Website3115 Merryfield Row
San Diego, CA, 92121
United States
The latest articles about ERAS.
Summary of Nov 17's posts. Generated by AI.
Summary of Apr 28's posts. Generated by AI.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
Summary of Jan 8's posts. Generated by AI.
Summary of Apr 28's posts. Generated by AI.
Investors talking about ERAS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.